Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 49 | ECE2017 | Next issue

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

Card image cap
20-23 May 2017, Lisbon, Portugal Further information

Guided Posters


ea0049gp173 | Pituitary | ECE2017

A comparison of single-dose effects of short acting somatostatin analogs: octreotide vs pasireotide in patients with active acromegaly after surgical debulking

Majos Agnieszka , Stelmachowska-Banas Maria , Czajka-Oraniec Izabella , Zgliczynski Wojciech

Acromegaly is a rare endocrine disorder caused by growth hormone (GH) secreting pituitary adenoma. The treatment of choice is transsphenoidal surgery. In patients with persistent disease after surgery medical therapy is recommended. First-line medical treatment include first generation long-acting somatostatin analogs: octreotide LAR and lanreotide autogel. Recently, pasireotide – a second generation somatostatin analog has been investigated in patients with acromegaly.</...

ea0049gp174 | Pituitary | ECE2017

Efficacy and safety of switching to pasireotide LAR alone or in combination with pegvisomant in acromegaly patients controlled with combination treatment of first-generation somatostatin analogues and weekly pegvisomant (PAPE study): a prospective open-label 48 week study, preliminary results 24 weeks

Muhammad Ammar , van der Lely Aart Jan , Janssen Joop , Neggers Sebastian

Background: Efficacy and safety of combination treatment of pasireotide LAR with pegvisomant (PEGV) has not been studied yet. Switching to Pasireotide LAR in patients previously controlled with long-acting somatostatin analogues (LA-SSAs) and PEGV could reduce the required PEGV dose to normalize serum IGF1 levels, while the effect on glucose metabolism is unknown.Methods: We enrolled 60 acromegaly patients >18 years with acromegaly who had normal IGF...

ea0049gp175 | Pituitary | ECE2017

Resistance to somatostatin analogues is associated with GSTP1 gene methylation and AHR rs2066853 variant in acromegaly patients

Ferrau Francesco , Romeo Petronilla Daniela , Puglisi Soraya , Ragonese Marta , Spagnolo Federica , Ientile Riccardo , Picerno Isa Anna Maria , Curro Monica , Visalli Giuseppa , Alibrandi Angela , Cannavo Salvatore

Evidences suggest that environmental contaminants exposure and/or the impairment of intracellular xenobiotic metabolizing system could affect pituitary pathophysiology. Glutathione-S-transferase-P1 (GSTP1) gene encodes for an enzyme that is involved in cellular detoxification mechanisms. GSTP1 altered activity or expression has been reported in some tumours.We aimed to assess the GSTP1 gene promoter methylation status in acromegaly patients and its contr...

ea0049gp176 | Pituitary | ECE2017

Minimally Invasive Diagnosis and Direct Transnasal Surgery: a single centre series of 100 children with Cushing’s Disease with long term follow-up

Crock Patricia , Ludecke Dieter K , Knappe Ulrich , Flitsch Joerg , Saeger Wolfgang

Introduction: Trans-sphenoidal surgery (TSS) with minimally invasive techniques is the first choice in the treatment of paediatric Cushing’s disease (CD). The question is how can high remission rates be achieved with less invasive investigations and TSS. The developments in our centre treating 100 pediatric Cushing patients with long-term follow-up may add some helpful ideas.Material and methods: Data from our first series 1 (n=55) will be ...

ea0049gp177 | Pituitary | ECE2017

Octreotide subcutaneous (s.c.) depot, a novel ready-to-use formulation, provides higher exposure and maintains response in patients with acromegaly and functioning neuroendocrine tumours (NETs) previously treated with long-acting octreotide: Results from a phase 2, open-label, multicentre, randomized study

Ferone Diego , Borson-Chazot Francoise , Cailleux Anne , Horsch Dieter , lahner Harald , Pivonello Rosario , Tauchmanova Libuse , Darstein Christelle , Olsson Hakan , Tiberg Fredrik , Pavel Marianne

Background: Octreotide s.c. depot is a novel, ready-to-use formulation administered via a thin needle, which may allow self-administration. In a phase 1 study in healthy volunteers, octreotide s.c. depot provided greater bioavailability with faster onset and greater IGF1 suppression than long-acting octreotide. Here, we present data from a phase 2 study evaluating pharmacokinetics (PK), efficacy, safety, and tolerability of octreotide s.c. depot in patients with acromegaly and...

ea0049gp178 | Pituitary | ECE2017

Sleep patterns in patients with non-functional GHRH receptor

Oliveira Francielle T , Salvatori Roberto , Marcondes Jose , Macena Larissa B , Oliveira-Santos Alecia A , Faro Augusto C N , Campos Viviane C , Oliveira Carla R P , Costa Ursula M M , Aguiar-Oliveira Manuel H

Hypothalamic GH releasing hormone (GHRH) has hypnotic actions by increasing slow wave sleep (SWS) (non-rapid eye movement sleep, non-REM), which account for about 75% of sleep. Conversely, GH may stimulate the rapid eye movement sleep (REM). Patients with GH deficiency (GHD) often exhibit sleep problems leading to daytime fatigue and reduced quality of life (QoL). We have described a cohort of patients with isolated GHD (IGHD) due to GHRH resistance caused by a homozygous null...

ea0049gp179 | Pituitary | ECE2017

Correction of sustained hyponatremia secondary to SIAD by the use of chronic tolvaptan therapy is associated with a reduction in Emergency Room visits, hospital admissions and days of hospitalization over a 3-year period

Hernandez Martin Cuesta , Hernandez Irene Crespo , Alemany Pablo Amich , Hoyos Emilia Gomez , Gomez Nancy Sanchez , Santiago Alejandro , De Miguel Novoa Paz , Calle-Pascual Alfonso Luis , de la Vega Isabelle Runkle

Introduction: Hyponatremia (HN) is associated with worse clinical outcomes, and longer hospital lengths-of-stay than seen in eunatremic patients. The Syndrome of Inappropriate Antidiuresis (SIAD) is the most common cause of hyponatremia in hospitalization. We studied the relationship between correction of sustained SIAD-induced hyponatremia and visits to the Emergency Room (ERv) as well as hospital admissions (HA) in a case series.Methods: Retrospective,...

ea0049gp180 | Pituitary | ECE2017

Outcome of non-functioning pituitary adenomas that regrow after primary treatment: a study from two large specialist UK centers

Tampourlou Metaxia , Ntali Georgia , Ahmed Shahzada , Arlt Wiebke , Ayuk John , Byrne James , Chavda Swarupsinh , Cudlip Simon , Gittoes Neil , Grossman Ashley , Mitchell Rosalind , O'Reilly Michael , Paluzzi Alessandro , Toogood Andrew , Wass John , Karavitaki Niki

Introduction: Despite the significant risk of regrowth of non-functioning pituitary adenomas (NFAs) after primary treatment, systematic data on the probability of further tumour progression and the effectiveness of management approaches are lacking.Aims: Assess the probability of further regrowth(s), predictive factors and outcomes of management approaches in patients with NFA diagnosed with adenoma regrowth after primary treatment (surgery combined or n...

ea0049gp181 | Pituitary | ECE2017

Targeting either GH or IGF-I levels during somatostatin analogue treatment in patients with acromegaly: A randomized, investigator-initiated multicenter study

Dal Jakob , Klose Marianne , Heck Ansgar , Andersen Marianne , Kistorp Caroline , Nielsen Eigil Husted , Bollerslev Jens , Feldt-Rasmussen Ulla , Jorgensen Jens Otto Lunde

Context: Assessment of disease control in acromegaly depends on GH and IGF-I, but discordant values frequently occur. Further, the role of OGTT-suppressed GH (GHnadir) in somatostatin analogue (SA) treated patients is debated.Objective: To evaluate the effect of targeting either IGF-I or GH during SA treatment.Design: A randomized, investigator-initiated, multicentre trial.Patients and methods: 84 ...

ea0049gp182 | Pituitary | ECE2017

Brain white matter damage and volumes of hippocampus and hypothalamus correlates to cognitive function in craniopharyngioma

Fjalldal Sigridur , Svard Daniel , Follin Cecilia , Westen Danielle Van , Gabery Sanaz , Petersen AEsa , Jansson Magdalena , Sundgren Pia Maly , Bjorkman-Burtscher Isabella , Latt Jimmy , Mannfolk Peter , Nordstrom Carl-Henrik , Rylander Lars , Ekman Bertil , Johansson Aki , Erfurth Eva-Marie

Introduction: Adult patients with craniopharyngioma (CP) and hypothalamic (HT) damage have impaired cognitive function. The white matter (WM) changes behind these findings remain to be elucidated. Diffusion tensor imaging (DTI) is a MRI technique that quantifies microstructural damage in the WM. This is the first study of DTI, hippocampal (HC) and HT volume in relation to cognition in CP patients.Methods: A cross-sectional study of childhood onset CP was...

ea0049gp183 | Pituitary | ECE2017

Copeptin – a sensitive marker of an altered CRH-axis in pituitary disease

Lewandowski Krzysztof , Lewinski Andrzej , Skowronska-Jozwiak Elzbieta , Malicka Katarzyna , Horzelski Wojciech , Brabant Georg

Background: Copeptin (pre-proAVP) secreted in equimolar amounts with vasopressin (AVP) closely reflects AVP release. Previously it was shown that copeptin is stimulated in standard pituitary function tests acting through hypothalamic centres. Furthermore, copeptin has been shown to subtly mirror stress potentially mediated via CRH. To further test a potential direct interaction of CRH with copeptin release which could augment AVP effects on pituitary function, we investigated ...

ea0049gp184 | Pituitary | ECE2017

Hormonal and metabolic effects of long-term cabergoline withdrawal in patients with hyperprolactinemia

Auriemma Renata Simona , Blasio Chiara , Grasso Ludovica Francesca Stella , Galdiero Mariano , Negri Mariarosaria , Pivonello Claudia , Granieri Luciana , Colao Annamaria , Pivonello Rosario

Hyperprolactinemia is associated with abnormalities in glucose and lipid profile with development of insulin resistance and metabolic syndrome (MetS), which have been found to be improved by treatment with cabergoline (CAB). The current study aimed at investigating hormonal and metabolic effects of long-term CAB withdrawal in patients with prolactinomas. In 46 patients (37 F, 9 M, aged 34.5±11.5 yrs, 36 microadenomas and 10 macroadenomas) anthropometric (weight, BMI, wais...